Poolbeg Pharma (LON:POLB) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Poolbeg Pharma PLC (LON:POLB)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 6.11 and traded as low as GBX 6. Poolbeg Pharma shares last traded at GBX 6, with a volume of 879,493 shares traded.

Analysts Set New Price Targets

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, September 24th.

Poolbeg Pharma Price Performance

The firm has a fifty day simple moving average of GBX 7.41 and a 200 day simple moving average of GBX 6.12. The company has a market cap of £46.19 million, a price-to-earnings ratio of -7.66 and a beta of 1.84.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.28) earnings per share for the quarter. Analysts expect that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.